This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 18, 2021
PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant
Author(s)BioPharm International Editors
Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
Advertisement
Analysis by Public Health England (PHE) has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
The real-world data, which were announced in a June 14, 2021 press release, have shown that two doses of the Pfizer-BioNTech vaccine are 96% effective at preventing hospitalization and two doses of the Oxford-AstraZeneca vaccine are 92% effective against hospitalization due to the Delta variant of COVID-19. These results are comparable with the efficacy found against hospitalization from the Alpha variant of the virus.
As of yet, the level of protection offered by the vaccines against mortality from the Delta variant is not known, but further work is underway to establish these data also. However, it is anticipated that the vaccines’ level of protection against mortality will also be high, as has been the case with other variants.
“These hugely important findings confirm that the vaccines offer significant protection against hospitalization from the Delta variant,” said Mary Ramsay, head of Immunisation at PHE, in the press release. “The vaccines are the most important tool we have against COVID-19. Thousands of lives have already been saved because of them.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5